AnodyneWiki

Methylphenidate

MPH
Methylphenidate
Salts
[]
Methylphenidate hydrochloride
Methylphenidate hydrochloride
Molecular structure drawn from PubChem coordinates
Rotamer
[]
Conformer structure via 3Dmol.js
Enable javascript to view conformer structure via 3Dmol.js
Physical properties
[]
Molecular mass233.31 g/mol [1]
AppearanceCrystals from ethanol (aqueous) [1]
Melting point74-75 °C [1]
Boiling pointBP: 135 to 137 °C at 0.6 mm Hg [1]
DecompositionWhen heated to decomposition it emits toxic fumes of nitroxides. [1]
Solubility1255mg/L [1]
Predicted LogP0.2 [1]
Structural Identifiers
[]
Molecular formulaC14H19NO2
IUPAC namemethyl 2-phenyl-2-piperidin-2-ylacetate
SMILESCOC(=O)C(C1CCCCN1)C2=CC=CC=C2
InChIInChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3
InChIKeyDUGOZIWVEXMGBE-UHFFFAOYSA-N
CAS number113-45-1
UNII207ZZ9QZ49
PubChem CID4158
Pharmacokinetics[]
Onset~20–60 minutes, depending on formulation
Elimination half-life2—3 hours
Duration of actionImmediate Release dosing: 3–4 hours, Extended Release dosing: 8–12 hours
MetabolismLiver (80%) mostly CES1-mediated
ExcretionUrine (90%)
Routes of administrationMedical: Oral, transdermal, Recreational: Oral, insufflation, sublingual, rectal, intravenous
Dependence liabilityPhysical: None, Psychological: Moderate[3]
Addiction liabilityModerate
Toxicity
[]
Mice:
- oral: 190 mg/kg
Mouse:
- oral: 190 mg/kg /Methylphenidate
- ip: 32 mg/kg
- sc: 218 mg/kg
- iv: 41 mg/kg
Rat:
- ip: 430 mg/kg
 [1]
Dosing[]
Buccal
[]
Light≤ 31.6 mg(12x - 33.3%)
Common31.6 - 40 mg(8x - 22.2%)
Strong40 - 60 mg(10x - 27.8%)
Heavy60 - 85 mg(2x - 5.6%)
Extreme85 mg +(4x - 11.1%)
Insufflated
[]
Light≤ 32.7 mg(76x - 30.4%)
Common32.7 - 40 mg(64x - 25.6%)
Strong40 - 60 mg(49x - 19.6%)
Heavy60 - 116.3 mg(35x - 14.0%)
Extreme116.3 mg +(26x - 10.4%)
Intravenous
[]
Light≤ 8.8 mg(1x - 25.0%)
Common8.8 - 10 mg(2x - 50.0%)
Strong10 - 15 mg
Heavy15 - 24 mg
Extreme24 mg +(1x - 25.0%)
Subcutaneous
[]
Light≤ 40.9 mg(2x - 66.7%)
Common40.9 mg
Strong40 - 50 mg
Heavy50 - 56 mg
Extreme56 mg +(1x - 33.3%)
Sublingual
[]
Light≤ 34.5 mg(74x - 27.2%)
Common34.5 - 40 mg(80x - 29.4%)
Strong40 - 60 mg(53x - 19.5%)
Heavy60 - 98 mg(37x - 13.6%)
Extreme98 mg +(28x - 10.3%)
Oral
[]
Light≤ 24.8 mg(122x - 43.1%)
Common24.8 - 36 mg(37x - 13.1%)
Strong36 - 72 mg(57x - 20.1%)
Heavy72 - 108 mg(40x - 14.1%)
Extreme108 mg +(27x - 9.5%)
Statistically derived dosages via DBI-IGS (archived by anodyne.wiki)
We do not take any responsibility for medical complications or loss of life sustained by following these dosages blindly.

Methylphenidate (also known as Methylphenidan, Phenidylate, Calocain, Plimasine, Daytrana, Methyl phenidylacetate, Metilfenidato, Methylphenidatum, 4311/B Ciba or Methyl phenidate) is a stimulant substance of the phenidate class.

Chemistry

Salts []

Methylphenidate is typically found in the form of its hydrochloride salt.

 []

Methylphenidate is a racemic mixture of the (optical activity ( + / - )).

Methylphenidate matches Lipinski's rule of five.

There are currently 8 reagent-interactions on

ReagentColor changeDescription
Marquislight orange
Mandelinshort reddish
Liebermannyellow - orange
Froehdeno color change -> Tan
Simon'spale violet
Hofmannno color change
Scottno color change
Zimmermannslow purple

Pharmacology

Mechanism of action []

While its exact mechanism is unclear, methylphenidate (MPH) has been shown to act as a norepinephrine and dopamine reuptake inhibitor (NDRI), thereby increasing the presence of these neurotransmitters in the extraneuronal space and prolonging their action. There is a dose-related effect of psychostimulants on receptor stimulation, where higher doses are shown to increase norepinephrine (NE) and dopamine (DA) efflux throughout the brain which can result in impaired cognition and locomotor-activating effects. In contrast, low doses are found to selectively activate NE and DE neurotransmission within the prefrontal cortex which is an area of the brain thought to play a prominent role in ADHD pathophysiology, thereby improving clinical efficacy and preventing side effects. The lower doses used to treat ADHD are not associated with the locomotor-activating effects associated with higher doses and instead reduce movement, impulsivity, and increase cognitive function including sustained attention and working memory. Methylphenidate's beneficial effects in sustaining attention have also been shown to be mediated by alpha-1 adrenergic receptor activity. Clinical findings have shown that children with ADHD have an abnormality in the dopamine transporter gene (DAT1), the D4 receptor gene (DRD-4), and/or the D2 receptor gene that may be at least partly overcome by the dopaminergic effects of methylphenidate, suggesting a possible mode of action. [1]

Interactions []

Interaction mechanisms documented in (number of interacting drugs):

shared target110
shared target10

Medical side effects []

311 side effects listed on drug labels in (methylphenidate).

  • Nervous system disorder
  • Mental disorder
  • Gastrointestinal disorder
  • Decreased appetite
  • Anorexia
  • Appetite absent
  • Headache
  • Malnutrition
  • Dry mouth
  • Mediastinal disorder
  • Dyspepsia
  • Nausea
  • Abdominal pain upper
  • Stomach ache
  • Anxiety
  • Hyperhidrosis
  • Sweating
  • Toothache
  • Sleep disorder
  • Insomnia
  • Blood pressure fluctuation
  • Lethargy
  • Asthenia
  • Fatigue
  • Initial insomnia
  • Infestation
  • Laryngeal pain
  • Nervousness
  • Feeling jittery
  • Palpitations
  • Agitation
  • Hyperkinesia
  • Nasopharyngitis
  • Vomiting
  • Tremor
  • Diarrhoea
  • Infection
  • Body temperature increased
  • Hypertension
  • Upper respiratory tract infection
  • Excoriation
  • Motion sickness
  • Application site reaction
  • Eye pain
  • Cough
  • Cough increased
  • Dizziness
  • Syncope
  • Muscle tightness
  • Thirst
  • Bruxism
  • Connective tissue disorder
  • Libido decreased
  • Disturbance in sexual arousal
  • Vertigo
  • Vision blurred
  • Constipation
  • Irritability
  • Affect lability
  • Mood swings
  • Oropharyngeal pain
  • Throat sore
  • Sinusitis
  • Panic attack
  • Abdominal discomfort
  • Upset stomach
  • Menopausal symptoms
  • Hot flush
  • Confusional state
  • Feeling abnormal
  • Malaise
  • Dyspnoea
  • Pain
  • Paraesthesia
  • Tension headache
  • Tension
  • Muscle spasms
  • Cramp muscle
  • Cramps of lower extremities
  • Alanine aminotransferase increased
  • Erectile dysfunction
  • Somnolence
  • Drowsiness
  • Depression
  • Abdominal pain
  • Gastrointestinal pain
  • Aggression
  • Alopecia
  • Anaphylactic shock
  • Anaemia
  • Aplastic anaemia
  • Angina pectoris
  • Angioedema
  • Arrhythmia
  • Arthralgia
  • Musculoskeletal discomfort
  • Myalgia
  • Bone disorder
  • Breast disorder
  • Cerebral arteritis
  • Chest pain
  • Chest discomfort
  • Chest pain exertional
  • Contusion
  • Sudden death
  • Dermatitis
  • Rash
  • Dermatitis exfoliative
  • Diplopia
  • Dyskinesia
  • Eczema
  • Oedema
  • Grand mal convulsion
  • Erythema multiforme
  • Stevens-Johnson syndrome
  • Eruption
  • Eye disorder
  • Hallucination
  • Cardiac arrest
  • Cardiac disorder
  • Haemorrhage
  • Haemoglobin
  • Coma hepatic
  • Hypersensitivity
  • Hypoglycaemia
  • Immune system disorder
  • Inflammation
  • Leukopenia
  • Mydriasis
  • Neuroleptic malignant syndrome
  • Obsessive-compulsive disorder
  • Pancreatitis
  • Pancytopenia
  • Priapism
  • Psychotic disorder
  • Convulsion
  • Completed suicide
  • Suicide attempt
  • Swelling
  • Tachycardia
  • Supraventricular tachycardia
  • Thrombocytopenia
  • Tourette's disorder
  • Ulcer
  • Erythema
  • Urticaria
  • Angiopathy
  • Weight increased
  • Weight decreased
  • Sudden cardiac death
  • Hepatic function abnormal
  • Migraine
  • Ventricular extrasystoles
  • Growth retardation
  • Blood alkaline phosphatase increased
  • Accommodation disorder
  • Dermatitis contact
  • Skin hyperpigmentation
  • Leukoderma
  • Skin disorder
  • Scab
  • Drug eruption
  • Muscle twitching
  • Disorientation
  • Abnormal behaviour
  • Hallucination, auditory
  • Hallucination, visual
  • Discomfort
  • Therapeutic response decreased
  • Hepatic enzyme increased
  • Skin exfoliation
  • Peripheral coldness
  • Blood bilirubin increased
  • Induration
  • Papule
  • Mania
  • Extrasystoles
  • Depressed mood
  • Feeling sad
  • Feeling hot
  • Platelet count decreased
  • Hyperpyrexia
  • Suicidal ideation
  • Bradycardia
  • Blood pressure increased
  • Drug effect decreased
  • Visual impairment
  • Abnormal vision
  • Auricular swelling
  • Reversible ischaemic neurological deficit
  • White blood cell count abnormal
  • Drug interaction
  • Thrombocytopenic purpura
  • Vasculitis necrotising
  • Suicidal behaviour
  • Logorrhoea
  • Cerebrovascular disorder
  • Cerebrovascular accident
  • Vasculitis
  • Hallucination, tactile
  • Choreoathetosis
  • Cerebral haemorrhage
  • Abscess
  • Albuminuria
  • Anger
  • Asthma
  • Back pain
  • Bronchitis
  • Neck pain
  • Coma
  • Conjunctivitis
  • Dehydration
  • Delirium
  • Dental caries
  • Depersonalisation
  • Diabetes mellitus
  • Dysmenorrhoea
  • Ear disorder
  • Ear pain
  • Ecchymosis
  • Epistaxis
  • Flushing
  • Gastritis
  • Gastroenteritis
  • Glaucoma
  • Gynaecomastia
  • Cardiac murmur
  • Blood disorder
  • Haematuria
  • Haemorrhoids
  • Hernia
  • Herpes virus infection
  • Hiccups
  • Hostility
  • Influenza
  • Laryngitis
  • Fungal infection
  • Myocardial infarction
  • Acute coronary syndrome
  • Nail disorder
  • Nasal congestion
  • Nasal polyps
  • Neoplasm
  • Neurosis
  • Obstruction
  • Otitis media
  • Pain in extremity
  • Personality disorder
  • Petechiae
  • Pharyngitis
  • Pneumonia
  • Pruritus
  • Psoriasis
  • Anorectal disorder
  • Rhinitis
  • Serum sickness
  • Speech disorder
  • Stereotypy
  • Shock
  • Loss of consciousness
  • Attention deficit/hyperactivity disorder
  • Urethral disorder
  • Urinary tract disorder
  • Peripheral vascular disorder
  • Chills
  • Skin odour abnormal
  • Apathy
  • Flat affect
  • Rash pustular
  • Benign neoplasm
  • Corneal lesion
  • Injury
  • Liver function test abnormal
  • Adverse reaction
  • Hyperreflexia
  • Skin discolouration
  • Skin irritation
  • Photosensitivity reaction
  • Photosensitivity
  • Rash macular
  • Ill-defined disorder
  • Weight gain poor
  • Increased appetite
  • Thinking abnormal
  • Mental disability
  • Abnormal dreams
  • Hypervigilance
  • Euphoric mood
  • Gastrointestinal obstruction
  • Lip swelling
  • Hypomania
  • Oropharyngeal discomfort
  • Hepatobiliary disease
  • Dry eye
  • Cardiac death
  • Akathisia
  • Crying
  • Tearfulness
  • Ligament sprain
  • Lymphadenopathy
  • Paralysis
  • Ear infection
  • Poisoning
  • Tic
  • Vocal tic
  • Local reaction
  • Libido disorder
  • Sympathomimetic effect
  • Sensitisation
  • Drug dependence
  • Overdose

Indications

  • Attention deficit disorder
  • Attention deficit/hyperactivity disorder
  • Brain injury
  • Cardiovascular disorder
  • Cerebral dysfunction
  • Daytime sleepiness
  • Distractibility
  • Drowsiness
  • Electroencephalogram abnormal
  • Forgetfulness
  • Heart malformation
  • Hyperkinesia
  • Learning disability
  • Mental disorder
  • Minimal brain dysfunction
  • Mood swings
  • Narcolepsy
  • Psychotic disorder
  • Sudden death
  • Ventricular arrhythmia

Subjective effects []

0xea / Methylphenidate []
Routes:
  • Oral
  • Intravenous (5 - 20mg)
Classes:Forms:
  • Hydrochloride
Indication:
  • executive dysfunction
Effects:
a1ko / Methylphenidate []
Routes:
  • Insufflated (30 - 60mg)
  • Oral (30 - 60mg)
alina / Methylphenidate []
Routes:
  • Insufflated (10.0mg)
  • Oral (5 - 20mg)
bonzi / Methylphenidate []
Routes:
  • Oral (5 - 10mg)
  • Insufflated (5mg)
emily / Methylphenidate []
Routes:
  • Oral (10 - 50mg)
magnus / Methylphenidate []
Routes:
  • Oral
  • Insufflated
Forms:
  • Hydrochloride
Effects:
Mere / Methylphenidate []
michalina / Methylphenidate []
nervewing / Methylphenidate []
ninerik / Methylphenidate []
Routes:
  • Oral (10mg)
Classes:Source:
  • Friend
Effects:
Pilz / Methylphenidate []
Routes:
  • Oral (5 - 38mg)
Forms:
  • Hydrochloride
Source:
  • Kinecteen tablets
  • Medikinet capsules
Indication:Effects:Notes:
  • Good ADHD-Medication
  • From the available preparations i would recommend concerta/kinecteen
  • Social interactions can feel difficult
vivi / Methylphenidate []
Routes:
  • Oral (5 - 40mg)
  • Insufflated (2.5 - 5mg)

Experience reports

Reddit

There are currently 21 trip reports involving methylphenidate on : []

 []

  • Australia: Methylphenidate is a Schedule 8.
  • Brazil: Methylphenidate is a A3.[4]
  • Canada: Methylphenidate is a Schedule III.[5][6][7]
  • Germany: Methylphenidate is a Anlage III under the "Betäubungsmittelgesetz (BtMG)".
  • United Kingdom: Methylphenidate is a Class B under the "Misuse of Drugs Act 1971".
  • New Zealand: Methylphenidate is a Class B2 -authority required.[8]
  • United States: Methylphenidate is a Schedule II under the "Controlled Substances Act".[9]
  • European Union: Methylphenidate is Prescription only.
  • United Nations: Methylphenidate is a Schedule II psychotropic under the "Convention on Psychotropic Substances 1971".
  • Other: Methylphenidate is a SE: Förteckning II MX: Controlled (estupefaciente).[10][11]

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 4158, Methylphenidate. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/4158
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Methylphenidate. UNII: 207ZZ9QZ49. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/207ZZ9QZ49
  3. Stahl SM. Prescriber's Guide: Stahl's Essential Psychopharmacology. Cambridge University Press. April 2024.
  4. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 31 March 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
  5. Ritalin Product information. Health Canada. 25 April 2012. https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=800
  6. Controlled Drugs and Substances Act. Justice Laws Website. 31 March 2022. https://laws-lois.justice.gc.ca/eng/acts/C-38.8/FullText.html
  7. Mental health. Health Canada. 9 May 2018. https://www.canada.ca/en/services/health/drug-health-products/drug-medical-device-highlights-2017/approved-drugs/mental-health.html
  8. Ritalin® (IR and LA). Medsafe NZ. https://www.medsafe.govt.nz/profs/datasheet/r/RitalintabSRtabLAtab.pdf
  9. Finlator J. Phenmetrazine and its salts, and Methylphenidate. Federal Register. 28 October 1971. https://archives.federalregister.gov/issue_slice/1971/10/28/20685-20687.pd#page=2f
  10. Ritalin®, Tablett 10 mg. FASS. 10 September 2025. https://fass.se/health/product/20040607007433/fass-text
  11. Ley General de Salud. Cámara de Diputados del H. Congreso de la Unión. 15 January 2026. https://www.diputados.gob.mx/LeyesBiblio/pdf/LGS.pdf

Data sources []

SourceStatusUpdated (UTC)
dosingok2026-11-20 10:23:35
drugsprook2026-11-20 10:23:31
erowidmissing (no Erowid substance of that name)2026-11-20 10:23:31
gsrsok2026-11-20 10:23:32
hmdbmissing (hmdb.ca refused automated access to HMDB0014566)2026-11-20 10:23:31
keggok2026-11-20 10:23:34
pubchemok2026-11-20 10:23:30
redditok2026-11-20 10:23:31
siderok2026-11-20 10:23:31
structureok2026-11-20 10:23:31
wikipediaok2026-11-20 10:23:31